Skip to main content
Clinical Trials/NCT05394246
NCT05394246
Recruiting
Not Applicable

Intraoperative Liver Tumor Imaging Using Fluorescent-labeled Human IgG

Chinese Academy of Sciences1 site in 1 country60 target enrollmentMay 20, 2022
ConditionsLiver Cancer
InterventionsFluoAB
DrugsFluoAB

Overview

Phase
Not Applicable
Intervention
FluoAB
Conditions
Liver Cancer
Sponsor
Chinese Academy of Sciences
Enrollment
60
Locations
1
Primary Endpoint
Tumor imaging precision
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma).

The main purposes of this study include:

  • To validate the safety and effectiveness of using FluoAB in hepatic surgery.
  • To raise the surgical precision with guidance by FluoAB fluorescence imaging.
Registry
clinicaltrials.gov
Start Date
May 20, 2022
End Date
June 30, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zeyu Zhang, PHD

Principal Investigator

Chinese Academy of Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients who have been diagnosed with liver tumor.
  • Planned to receive hepatectomy.
  • Liver function Child-Pugh A/B.
  • The expected lifetime is longer than 6 months.
  • Approved to sign the informed consent.

Exclusion Criteria

  • Enrolled in other trials in the past 3 months.
  • Metastatic lesions were found.
  • Undesirable function of heart, lung, kidney, or any other organs.
  • Unable to tolerate a hepatectomy.
  • The researchers considered inappropriate to be included.

Arms & Interventions

FluoAB intraoperative fluorescence imaging

The patients will receive an injection of FluoAB. Surgery will be performed with guidance by FluoAB fluorescence imaging.

Intervention: FluoAB

Outcomes

Primary Outcomes

Tumor imaging precision

Time Frame: Update with an average of 2 weeks.

Sensitivity and specificity of hepatic malignancy detection by fluoAB intraoperative imaging.

Tumor lesions

Time Frame: Immediately after the hepatic surgery.

Numbers of intraoperatively detected tumor lesions.

Study Sites (1)

Loading locations...

Similar Trials